---
schema_version: "secwatch.filing_event.v1"
accession: "0000950142-23-001396"
form_type: "8-K"
ticker: "LAB"
cik: "0001162194"
company_name: "STANDARD BIOTOOLS INC."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T08:15:29.317666+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Standard BioTools Q1 core revenue up 1.8% YoY; operating cash burn cut 55.8% sequentially

## Summary
- GAAP revenue $25.1M (-5.2% YoY); core product/service revenue $24.3M (+1.8% YoY).
- GAAP product margin 46.6% (+567 bps QoQ); non-GAAP margin 60.9% (+792 bps QoQ).
- Operating cash burn $8.5M, down from $19.2M in Q4 2022 and $15.6M in Q1 2022.
- Launched Hyperion XTi Imaging System; subleased 50% of SSF space; repurchased 1.3M shares for $2.5M.
- FY2023 guidance: flat-to-moderate core revenue growth; GAAP opex $118-123M.

## SEC filing metadata
- accession: 0000950142-23-001396
- form_type: 8-K
- ticker: LAB
- cik: 0001162194
- company_name: STANDARD BIOTOOLS INC.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1162194/000095014223001396/0000950142-23-001396-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1162194/000095014223001396/eh230357220_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950142-23-001396
- JSON: https://secwatch.observer/filing/0000950142-23-001396.json
- Plain text: https://secwatch.observer/filing/0000950142-23-001396.txt

## Key facts
- Earnings Releases
  STANDARD BIOTOOLS INC. reported first quarter ended March 31, 2023 results: revenue $25.1 million.
  - Period: first quarter ended March 31, 2023
  - Revenue: $25.1 million
  - Result: reported results
  source text: in the fourth quarter and a 46% reduction from the $15.6 in the first quarter last year GAAP revenue (includes discontinued/COVID-19 products) decreased 5.2% year-over-year to $25.1 million, with a 1.8% year-over-year increase in ongoing, core product and service revenue to $24.3 million GAAP product and services margin of 46.6%, an improvement of 567 basis points
  evidence_url: https://www.sec.gov/Archives/edgar/data/1162194/000095014223001396/0000950142-23-001396-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.